These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21573251)

  • 1. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications.
    Murdaca G; Colombo BM; Puppo F
    Drugs Today (Barc); 2011 Apr; 47(4):277-88. PubMed ID: 21573251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update upon efficacy and safety of TNF-α inhibitors.
    Murdaca G; Colombo BM; Cagnati P; Gulli R; Spanò F; Puppo F
    Expert Opin Drug Saf; 2012 Jan; 11(1):1-5. PubMed ID: 22010813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP; Liossis SN; Sfikakis PP
    QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
    Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
    Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
    Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):11-32. PubMed ID: 24774504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events.
    Murdaca G; Colombo BM; Puppo F
    Int J Immunopathol Pharmacol; 2009; 22(3):557-65. PubMed ID: 19822072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F; Chiappelli M; Ianni M; Porcellini E
    Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab in the treatment of immune-mediated diseases.
    Lapadula G; Marchesoni A; Armuzzi A; Blandizzi C; Caporali R; Chimenti S; Cimaz R; Cimino L; Gionchetti P; Girolomoni G; Lionetti P; Marcellusi A; Mennini FS; Salvarani C
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):33-48. PubMed ID: 24774505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE
    Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].
    Régent A; Mouthon L
    Presse Med; 2009 May; 38(5):761-73. PubMed ID: 19349142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of the tumor necrosis factor antagonists.
    Bachmann F; Nast A; Sterry W; Philipp S
    Semin Cutan Med Surg; 2010 Mar; 29(1):35-47. PubMed ID: 20430306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.
    Jinesh S
    Inflammopharmacology; 2015 Jun; 23(2-3):71-7. PubMed ID: 25687751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness and safety of biological therapy with adalimumab].
    Fehér J; Lengyel G
    Orv Hetil; 2009 Jun; 150(26):1215-22. PubMed ID: 19546078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-α inhibitors and cutaneous carcinoma risk.
    Zitelli KB; Zedek D; Ranganathan P; Amerson EH
    Cutis; 2013 Jul; 92(1):35-9. PubMed ID: 23961524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.